Literature DB >> 984072

Hypertension associated with early stage kidney disease. Complementary roles of circulating renin, the body sodium/volume state and duration of hypertension.

C Beretta-Piccoli, P Weidmann, R De Châtel, F Reubi.   

Abstract

Interrelations among blood pressure, exchangeable sodium, blood volume and plasma renin activity were studied in 40 normal subjects and in 40 patients with early stage kidney disease (mean plasma creatinine, 2 mg/100 ml). Findings in eight normotensive patients did not differ significantly from those in normal subjects. However, 32 hypertensive patients showed increases (p less than 0.05) in mean exchangeable sodium and in the products of the logarithm of plasma renin activity and exchangeable sodium or blood volume. In normal subjects, blood pressure did not correlate with any of the parameters measured. In the patients, it correlated significantly (p less than 0.05) with duration of hypertension (r = 0.70), exchangeable sodium (r = 0.34) and with sodium-renin (r = 0.38) or volume-renin (r = 0.30) products, but not with blood volume or circulating renin individually. Multiple regression analysis with blood pressure as a dependent variable, and duration of hypertension and the sodium-renin or volume-renin products as independent variables, revealed correlation coefficients of 0.77 and 0.76, respectively. These findings suggest that hypertension accompanying early stage kidney disease may depend at least partly on subtle abnormalities in the sodium volume-renin feedback mechanism as well as on a factor related to the duration of preexisting hypertension.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 984072     DOI: 10.1016/0002-9343(76)90155-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  13 in total

1.  Interrelations between age and plasma renin, aldosterone and cortisol, urinary catecholamines, and the body sodium/volume state in normal man.

Authors:  P Weidmann; R de Chatel; A Schiffmann; E Bachmann; C Beretta-Piccoli; F C Reubi; W H Ziegler; W Vetter
Journal:  Klin Wochenschr       Date:  1977-08-01

2.  Renal protective effects of calcium antagonists?

Authors:  J H Bauer
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

3.  Hypoaldosteronism without hyperkalemia.

Authors:  P Weidmann; C Beretta-Piccoli; Z Glück; G Keusch; F C Reubi; R De Châtel; C Cottier
Journal:  Klin Wochenschr       Date:  1980-02-15

4.  Blood pressure may be sodium-dependent in diabetic patients without overt nephropathy.

Authors:  J A O'Hare; J B Ferriss; B M Twomey; M Cole; D Brady; D J O'Sullivan
Journal:  Ir J Med Sci       Date:  1985-12       Impact factor: 1.568

5.  Recent pathogenic aspects in essential hypertension and hypertension associated with diabetes mellitus.

Authors:  P Weidmann
Journal:  Klin Wochenschr       Date:  1980-10-01

6.  Sodium and potassium in essential hypertension.

Authors:  A F Lever; C Beretta-Piccoli; J J Brown; D L Davies; R Fraser; J I Robertson
Journal:  Br Med J (Clin Res Ed)       Date:  1981-08-15

7.  Interrelationships between sodium clearance, plasma aldosterone, plasma renin activity, renal hemodynamics and blood pressure in renal disease.

Authors:  F C Reubi; P Weidmann; Z Glück
Journal:  Klin Wochenschr       Date:  1979-12-03

8.  Renal protective effect of long term antihypertensive therapy with enalapril.

Authors:  J H Bauer; G P Reams
Journal:  Drugs       Date:  1988       Impact factor: 9.546

9.  Long term effects of sustained release verapamil on the renal and systemic haemodynamic parameters in hypertensive patients with mild to severe chronic renal failure.

Authors:  D C Schohn; H A Jahn; M Maareck
Journal:  Drugs       Date:  1993       Impact factor: 9.546

10.  Antihypertensive mechanism of the diuretic muzolimine in mild renal failure. Roles of sodium and cardiovascular norepinephrine responsiveness.

Authors:  H Schiffl; P Weidmann; C Beretta-Piccoli; C Cottier; A J Seiler; W H Ziegler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.